Stay updated on Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial
Sign up to get notified when there's something new on the Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial page.

Latest updates to the Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedA new NIH grant/contract identifier was added to the study's identifiers, and the page revision was updated to v3.6.6.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedRevision tag updated from v3.6.4 to v3.6.5, reflecting a minor platform update rather than changes to user-facing content.SummaryDifference0.0%

- Check52 days agoChange DetectedRevision: v3.6.4 is now shown in the page footer, replacing the previous v3.6.3. This reflects a minor version update to the site's interface rather than changes to the study data.SummaryDifference0.0%

- Check74 days agoChange DetectedThe website now displays Revision: v3.6.3, replacing the previous Revision: v3.6.2, indicating an update to the page's revision identifier rather than to study data or content.SummaryDifference0.0%

- Check81 days agoChange DetectedAn updated software build identifier (v3.6.2) is now displayed on the page, replacing the previous v3.6.0. This appears to be routine page maintenance and does not modify the study information or visible content.SummaryDifference0.0%

- Check95 days agoChange DetectedRecruitment status is updated to No longer looking for participants, reflecting that participant enrollment has ended. The page also adds new user-facing sections (How to Read a Study Record, Common Questions, How to Join a Study), reformats the Intervention/Treatment heading, and lists Revision: v3.6.0 as the current version.SummaryDifference0.3%

Stay in the know with updates to Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial page.